Red Light Holland (TSE:TRIP)
:TRIP
Top Page
Red Light Holland
(TRIP)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.03
▲(45.00% Upside)
Action:ReiteratedDate:04/01/26
The score is primarily constrained by weak financial performance (ongoing net losses and negative operating/free cash flow) despite strong revenue growth and low leverage. Technicals add a modest headwind with the stock trading below key moving averages, and valuation is limited by negative earnings and no indicated dividend yield.
Positive Factors
Low Leverage / Strong Balance Sheet
Low leverage gives the company durable financial flexibility and downside protection. With small TTM debt versus equity the firm is better able to manage operational setbacks, access credit or finance strategic investments over months without immediate solvency pressure, supporting resilience.
Negative Factors
Persistent Net Losses and Cash Burn
Ongoing deep losses and negative operating cash flow mean the company remains cash-burning. Over months this erodes liquidity and forces reliance on external financing or dilution, which constrains capital for R&D, scaling, regulatory compliance and limits strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Low leverage gives the company durable financial flexibility and downside protection. With small TTM debt versus equity the firm is better able to manage operational setbacks, access credit or finance strategic investments over months without immediate solvency pressure, supporting resilience.
Read all positive factors
Red Light Holland (TRIP) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$12.77M
Dividend YieldN/A
Average Volume (3M)212.42K
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue Growth-28.00%
EPS Growth38.46%
CountryCA
Employees104
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding425,710,720
10 Day Avg. Volume258,444
30 Day Avg. Volume212,422
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)1.18
Price to Sales (P/S)4.99
P/FCF Ratio-6.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Red Light Holland Business Overview & Revenue Model
Company Description
Red Light Holland Corp. engages in the production, cultivation, and sale of magic truffles to the recreational market in the Netherlands. It is also involved in the selection, distribution, and export of truffles, cannabidiol products, cannabis se...
How the Company Makes Money
Red Light Holland primarily makes money by selling legal psilocybin truffle products and related branded offerings in jurisdictions where they are permitted, with its core commercial activity centered on the Netherlands’ legal market for psilocybi...
Red Light Holland Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
66
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.17M | 4.94M | 4.75M | 3.95M | 2.33M | 0.00 |
| Gross Profit | 1.27M | 1.91M | 2.02M | 1.71M | 617.68K | 0.00 |
| EBITDA | -4.36M | -3.35M | -6.58M | -4.32M | -8.55M | 0.00 |
| Net Income | -4.77M | -4.04M | -7.63M | -5.40M | -14.37M | -325.17K |
Balance Sheet | ||||||
| Total Assets | 18.20M | 21.22M | 24.08M | 30.14M | 32.94M | 3.97M |
| Cash, Cash Equivalents and Short-Term Investments | 9.88M | 12.27M | 14.17M | 18.53M | 26.62M | 1.96M |
| Total Debt | 501.66K | 2.18M | 1.72M | 1.77M | 1.50M | 86.77K |
| Total Liabilities | 3.58M | 3.87M | 3.82M | 3.80M | 3.78M | 5.11M |
| Stockholders Equity | 14.69M | 17.35M | 20.07M | 26.06M | 28.48M | -1.14M |
Cash Flow | ||||||
| Free Cash Flow | -2.69M | -2.01M | -3.92M | -6.45M | -5.28M | -238.35K |
| Operating Cash Flow | -2.51M | -1.48M | -3.23M | -4.39M | -4.88M | -238.35K |
| Investing Cash Flow | -1.16M | -525.40K | -650.43K | -3.17M | -582.74K | -1.80M |
| Financing Cash Flow | -490.68K | 445.17K | -206.95K | -114.16K | 451.76K | 4.01M |
Red Light Holland Technical Analysis
Positive
0.02
Price Trends
0.02
Positive
0.02
Positive
0.03
Positive
Market Momentum
<0.01
Negative
59.41
Neutral
83.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TRIP, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.41 is Neutral, neither overbought nor oversold. The STOCH value of 83.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:TRIP.
Red Light Holland Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | C$7.65M | 11.26 | -99.55% | ― | -26.71% | -988.89% | |
54 Neutral | C$129.34M | -1.92 | -275.39% | ― | -4.23% | 37.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$2.59B | -8.05 | -28.58% | ― | -3.38% | -31.35% | |
47 Neutral | C$16.74M | -4.56 | 899.59% | ― | ― | -80.42% | |
47 Neutral | C$70.56M | -1.02 | -80.81% | ― | 2.19% | -91.41% | |
46 Neutral | C$12.77M | -1.51 | -23.76% | ― | -28.00% | 38.46% |
* Healthcare Sector Average
TSE:TRIP
Red Light Holland
0.03
>-0.01
-14.29%
TSE:MUSH
Good Shroom Co Inc
0.15
0.10
196.00%
TSE:RVV
Revive Therapeutics
0.04
0.02
100.00%
TSE:CWEB
Charlotte's Web Holdings
0.81
0.71
671.43%
TSE:CURA
Curaleaf Holdings
3.34
2.27
212.15%
TSE:PLTH
Planet 13 Holdings
0.22
-0.08
-28.33%
Red Light Holland Corporate Events
Business Operations and StrategyM&A Transactions
Red Light Holland Touts Filament’s Expanding Global Psilocybin Trial Network
Positive
Apr 7, 2026
Red Light Holland, which is pursuing an acquisition of clinical-stage psychedelic developer Filament Health, is deepening its foothold in regulated psilocybin by tying its strategy to Filament’s patented botanical psilocybin candidate PEX010...
Business Operations and Strategy
Red Light Holland Backs UCSF Global Psychedelic Study via Filament Network
Positive
Apr 1, 2026
Red Light Holland said it will support the University of California, San Francisco’s Carhart-Harris Lab Global Psychedelic Study by working through Filament Health’s clinical network to circulate participation instructions to all resea...
Business Operations and StrategyM&A TransactionsShareholder Meetings
Red Light Holland Moves Closer to Acquiring Filament Health With Court Interim Order
Positive
Mar 23, 2026
Red Light Holland and Filament Health have secured an interim order from the Supreme Court of British Columbia, advancing Red Light’s proposed acquisition of all Filament common shares through a statutory plan of arrangement. The order permi...
Business Operations and Strategy
Red Light Holland Deploys Kala Bio AI Platform to Advance Psilocybin Drug PEX010
Positive
Mar 18, 2026
Red Light Holland has engaged Kala Bio’s Researgency.ai platform to support clinical development of PEX010, Filament Health’s patented botanical psilocybin drug candidate. The AI-driven system will assist with clinical planning, protoc...
Business Operations and StrategyFinancial Disclosures
Red Light Holland Narrows Focus as Q3 Revenue Rises but Profits Tighten
Neutral
Mar 3, 2026
Red Light Holland reported third-quarter 2026 results showing an 8.3% year-over-year revenue increase to $1.27 million, but a 13.7% decline in gross profit and a slightly higher adjusted EBITDA loss of $0.71 million, while cash fell to $9.24 milli...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.